Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bristol Myers Squibb
Biotech
Alumis beams as pivotal data on Sotyktu rival drive stock surge
Phase 3 psoriasis studies of Alumis’ TYK2 inhibitor hit their primary endpoints, setting the biotech up to file for approval of a Sotyktu challenger.
Nick Paul Taylor
Jan 6, 2026 9:05am
Takeda looks to 2026 FDA filing for Sotyktu rival zasocitinib
Dec 18, 2025 7:55am
Harbour BioMed docks with BMS in antibody research deal
Dec 17, 2025 8:55am
Fierce Pharma
With site 'irregularities,' BMS delays key Cobenfy readout
Dec 3, 2025 10:14am
BMS-J&J blood thinner fails phase 3, denting blockbuster hopes
Nov 14, 2025 8:10am
BMS boosts cancer trials with Sarah Cannon's platform
Nov 12, 2025 12:30pm
